(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Significant effort has been expended over the past decade to reduce racial disparities in breast cancer care. Whether disparities in receipt of appropriate radiotherapy care for breast cancer persisted despite these efforts is unknown, as is the impact of being eligible for Medicare.

Debra Nana Yeboa, MD, Xiao Xu, PhD, Beth A. Jones, PhD, MPH, Pamela Soulos, MPH, Cary Gross, MD, James B. Yu, MD; Yale School of Medicine

Background: Significant effort has been expended over the past decade to reduce racial disparities in breast cancer care. Whether disparities in receipt of appropriate radiotherapy care for breast cancer persisted despite these efforts is unknown, as is the impact of being eligible for Medicare. We therefore investigated trends in racial differences by age in post–breast lumpectomy radiation therapy (PLRT) from 2004–2009.

Methods: We analyzed the Surveillance, Epidemiology, and End Results (SEER) registry database for women aged 40–85 years who underwent lumpectomy for stage I breast cancer and were eligible for PLRT. We examined variables potentially associated with the receipt of PLRT, including year of diagnosis and race, and examined women separately by age group.

Results: Among 67,124 women aged 40–85 years undergoing lumpectomy, receipt of PLRT decreased from 80.7% in 2004 to 76.8% by 2009 (P < .001). There remained a persistent disparity in PLRT among African-American women (in 2004, 80.6% white vs 78.9% African Americans and in 2009, 77.5% white vs 72.0% African Americans). In multivariable logistic regression, African-American race (odds ratio [OR] = 0.82; 95% confidence interval [CI], 0.76–0.89) and being diagnosed more recently were associated with lower odds of PLRT (OR for 2009 vs 2004 = 0.74; 95% CI, 0.69–0.79), while older women typically covered by public health insurance (age 65–69) were more likely to receive PLRT (OR = 1.09; 95% CI, 1.02–1.15).

Conclusion: PLRT decreased by a significant percentage of 3.9% among all women in recent years, and racial disparities in PLRT receipt have persisted. Medicare eligibility increased the likelihood of PLRT receipt.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content